Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul;34(4):307-312.
doi: 10.6515/ACS.201807_34(4).20180306B.

Low Serum Adropin Levels are Associated with Coronary Slow Flow Phenomenon

Zi-Wen Zhao  1 , Yin-Gang Ren  2 , Jun Liu  2
Affiliations

Low Serum Adropin Levels are Associated with Coronary Slow Flow Phenomenon

Zi-Wen Zhao et al. Acta Cardiol Sin. 2018 Jul.

Abstract

Background: Adropin is a peptide hormone expressed in coronary artery endothelial cells, which plays a potential endothelial protective role. We sought to assess whether serum adropin levels are correlated with the coronary slow flow phenomenon (CSFP).

Methods: We enrolled 82 patients with angiographically confirmed CSFP and 184 age-matched controls. Serum adropin levels were measured by enzyme-linked immunosorbent assay (ELISA), and coronary flow rate was assessed using thrombolysis in myocardial infarction (TIMI) frame count (TFC). CSFP was defined as a corrected TIMI-TFC greater than two standard deviations from the normal range.

Results: Serum adropin levels were significantly lower in the CSFP patients (n = 82) than in the controls (n = 184) (4.03 ± 1.99 vs. 4.86 ± 1.88 ng/ml, p = 0.001). Multivariate logistic regression analysis revealed that serum adropin was the only independent negative predictor of CSFP (odds ratio 0.758, 95% confidence interval 0.647-0.888, p = 0.001). Serum adropin levels were independently and negatively correlated with mean TFC (r = -0.387, p < 0.001).

Conclusions: We demonstrated that decreased serum adropin levels were independently associated with the presence and severity of angiographically proven CSFP. These findings suggest that serum adropin may be a potential biomarker to provide valuable information regarding the prediction of CSFP.

Keywords: Adropin; Biomarker; Cardiovascular; Coronary slow flow phenomenon; Disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Correlations between serum adropin levels and mean-TFC. TFC, TIMI frame count.
See this image and copyright information in PMC

References

    1. Tambe AA, Demany MA, Zimmerman HA, et al. Angina pectoris and slow flow velocity of dye in coronary arteries--a new angiographic finding. Am Heart J. 1972;84:66–71. - PubMed
    1. Çetin M, Kiziltunc E, Elalmış ÖU, et al. Predictive value of neutrophil lymphocyte ratio and platelet lymphocyte ratio in patients with coronary slow flow. Acta Cardiol Sin. 2016;32:307–312. - PMC - PubMed
    1. Beltrame JF, Turner SP, Leslie SL, et al. The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon. J Am Coll Cardiol. 2004;44:57–62. - PubMed
    1. Wang Y, Ma C, Zhang Y, et al. Assessment of left and right ventricular diastolic and systolic functions using two-dimensional speckle-tracking echocardiography in patients with coronary slow-flow phenomenon. PLoS One. 2015;23:e0117979. - PMC - PubMed
    1. Horjeti B, Goda A. Acute ischemia manifestation in a patient with coronary slow flow phenomenon. J Electrocardiol. 2012;45:277–279. - PubMed

LinkOut - more resources